Amplichek II Quality Control for Molecular Diagnostics of HAIs
Bio-Rad Laboratories, Inc. have entered into the rapidly growing molecular diagnostics testing market with the launch of Amplichek™ II quality control, which was recently issued a de novoclearance from the FDA.
The FDA’s de novo clearance is a classification given to devices that are considered novel, with no existing classification or predicate device on the market. Amplichek II began shipping in May and is the first in a series of infectious disease controls that Bio-Rad plans to introduce for the molecular diagnostic testing market.
Amplichek II is an independent, multi-analyte quality control that monitors the performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of Healthcare Associated Infections (HAIs).
Tags: Clostridium difficile, Healthcare-associated Infections
Date Published: May 30, 2016
Source article link: Bio-Rad Laboratories » company contact details
Bruker Acquires MERLIN Adding Speciality AST and ART
New Primer Pairs for LDTs for P. jirovecii, Group C and G Strep
FDA Clearance for ARIES C. difficile Assay Detecting both Toxin A and B
COPAN Diagnostics Inc. Showcasing PhenoMATRIX™ Smart Algorithms at AACC in San Diego